JOHNSON & JOHNSON (JNJ)
US4781601046 - Common Stock
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
J&J, Merck Cut Jobs in China as Local Competition Takes Toll
Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs.
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and...
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of...
Noteworthy Thursday Option Activity: JNJ, APAM, CAPR
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JNJ July 2025 Options Begin Trading
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key...
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth.
Interesting JNJ Put And Call Options For February 2025
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced...
Johnson & Johnson Enters Oversold Territory (JNJ)
Johnson & Johnson Enters Oversold Territory
In trading on Monday, shares of Johnson & Johnson entered into oversold territory, hitting an RSI reading of 29.5
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and...
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
You'll also like these stocks for their track record of earnings growth.
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will...
Dow Movers: DOW, AXP
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges